Publications

1. Fishman, A., Bar-Kana, Y., Steinberger, I. and Lorberboum-Galski, H.: Increased cytotoxicity of interleukin 2-Pseudomonas exotoxin (IL2-PE40) chimeric proteins containing a targeting signal for lysosomal membranes. Biochemistry U.S.A. 33: 6235-6243, 1994.
2. Lorberboum-Galski, H.: Interleukin 2-Pseudomonas exotoxin A (IL2-PE40) chimeric protein for targeted immunotherapy and the study of immune responses. J. Toxicol.-Toxin Reviews 13(1): 105-109, 1994.
3. Volk, H.-D., Muller, S., Yarkoni, S., Diamantstein, T. and Lorberboum-Galski, H.: Mechanism of dichotomic action of interleukin-2-pseudomonas exotoxin 40 (IL2-PE40) on cell mediated and humoral immune response. J. Immunol. 153: 2497-2505, 1994.
4. BenEzra, D., Maftzir, G., Hochberg, E., Anteby, I. and Lorberboum-Galski, H.: Ocular distribution of the chimeric protein IL2-PE40. Curr. Eye Res. 14: 153-158, 1995.
5. Abdul-Hai, A., Lorberboum-Galski, H., Nechushtan, A., Weiss, L., Slavin, S. and Or, O.: Involvement of IL-2 in immunologic reconstitution following bone marrow transplantation in mice. J. Interferon and Cytokine Res. 15: 95-101, 1995.
6. Steinberger, I., Brenner, T. and Lorberboum-Galski, H.: Interleukin 2-Pseudomonas exotoxin chimeric protein is cytotoxic to B cell cultures derived from Myasthenia Gravis patients. J. Neurol. Sci., 133, 183-191, 1995.
7. Steinberger, I., Brenner, T. and Lorberboum-Galski, H.: Interleukin 2-Pseudomonas exotoxin (IL2-PE664Glu) chimeric protein kills B cells from patients with Myasthenia Gravis. Cellular Immunol. 169, 55-61, 1996.
8. Yarkoni, S., Lishner, M., Tangi, I., Nagler, A. Lorberboum-Galski, H.: B-cell Non-Hodgkin lymphoma: Evidence for the t(14;18) translocation in cell hematopoietic lineages. J. Nat. Canc. Inst. 88, 973-979, 1996.
9. Fishman, A. and Lorberboum-Galski, H.: Targeted elimination of cells expressing the high-affinity receptor for IgE (Fc RI) by a Pseudomonas exotoxin-based chimeric protein. Eur. J. Immunol. 27, 486-494, 1997.
10. Nechushtan, A., Yarkoni, S., Marianovksy and Lorberboum-Galski, H.: Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin throug specific gonadotropin-releasing hormone binding sites. J. Biol. Chem. 272, 11597-11603, 1997.
11. Steinberger, I., Ben-Bassat, H., Hochberg, E and Lorberboum-Galski, H.: Interleukin-2 (IL-2) receptor alpha, beta and gamma subunit expression as a function of B-cell lineage ontogeny: the use of IL-2-PE66(4Glu) to characterize internalization via IL-2 receptor subunits. Scan. J. Immunol. 46, 129-136, 1997.
12. Ben-Yehudah, A., Yarkoni, S., Nechushtan, A., Belostotsky, R. and Lorberboum-Galski, H.: Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med. Oncol. 16: 38-45, 1999.
13. Brenner, T., Steinberger, I., Soffer, D., Beraud, E., Ben-Nun, A., Lorberboum-Galski, H.: A novel antigen-toxin chimeric protein: Myelin Basic Protein-Pseudomonas exotoxin (MBP-PE40) for treatment of experimental autoimmune encephalomyelitis. Immunol. Letters, 68: 403-410, 1999.
14. Aqelian, R., Yarkoni, S. and Lorberboum-Galski, H. Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Letters 457: 271-276, 1999.
15. Fishman, A., Prus, D. Belostotsky, R. and Lorberboum-Galski, H. Targeted Fc2-3-PE chimeric protein abolishes passive cutaneous anaphylaxis in mice. Clinical Exp. Immunol. 119:398-403, 2000.
16. Azar, Y. and Lorberboum-Galski, H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis, 5, 531-542, 2000.
17. Ben-Yehudah, A., Prus, D. and Lorberboum-Galski, H. i.v. administration of L-GnRH-PE66 efficiently inhibits growth of colon adenocarcinom xenografts in nude mice. Int J Cancer, 92, 263-8, 2001.
18. Belostotsky, R. and Lorberboum-Galski, H. Apoptosis-Inducing Human-Origin Fc-Bak chimeric proteins for targeted elimination of Mast cells and Basophils: A new approach for Allergy treatment. J. Immunol. 167: 4719-4728, 2001.
19. Ben-Yehudah, A., Aqelian, R., Belostotsky, R., Azar, Y. and Lorberboum-Galski, H. Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins. BBRC. 290: 332-338, 2002.
20. Rami Aqeilan, Rotem Kedar Ahmi Ben-Yehudah and Haya Lorberboum-Galski. Mechanism of action of IL2-Bax; An apoptosis-inducing chimeric protein targeted against Interleukin-2 receptor expressing cells. Biochem. J., 370, 129-140, 2003.
21. Ahmi Ben-Yehudah, Rami Aqeilan, Dana Robashkevich and Haya Lorberboum-Galski. Utilizing apoptosis for targeted cancer therapy by a new GnRH-DFF40 chimeric protein. Clinical Cancer Research. 9, 1179-1190, 2003.
22. Belostotsky, R. and Lorberboum-Galski, H. Utilizing Fc epsilon-Bak chimeric protein for studying IgE-Fc epsilon RI interactions. Clinical Immunology, 110, 89-99, 2004.
23. Lichtenstein M, Ben-Yehudah A, Belostotsky R, Eaveri R, Sabag O, Grodzovski I, Lorberboum-Galski H. Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma. Int J Oncol., 27, 143-8, 2005.
24. Segel MJ, Aqeilan R, Zilka K, Lorberboum-Galski H, Wallach-Dayan SB, Conner MW, Christensen TG, Breuer R. Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury. Int J Exp Pathol. 86, 279-88, 2005.
25. Abdul-Hai A, Ben-Yehuda A, Galsky H, Slavin S, Or R. Interleukin 2 regulation following semi-allogeneic bone marrow transplantation in mice. Cancer Immunol Immunother. 2006, 1-7.

Review Articles

1. Ahmi Ben-Yehudah, Ruth Belostotsky, Michal Lichtenstein, Rami Aqeilan, Ronen Abady and Haya Lorberboum-Galski. Chimeric proteins as candidates for cancer Treatment. Drugs of the future 27, 851-861, 2002. Invited Review.
2. Ahmi Ben-Yehudah and Haya Lorberboum-Galski. Targeted Cancer Therapy with GnRH-Chimeric Proteins. Expert Rev. Anticancer Ther., 4, 151-161, 2004. Invited Review (peer Reviewed).
3. Eaveri, Ronen, Ben-Yehudah, Ahmi and Lorberboum-Gaski, H. (2004). Surface Antigens/Receptors for Targeted Cancer Treatment; The GnRH Receptor/Binding Site for Targeted Adenocarcinoma Therapy. Current Cancer Drug Targets, 4, 673-87. Invited Review (Peer reviewed).

Book Chapters

1. Ben Ezra, D., Yarkoni, S., Maftzir, G. and Lorberboum-Galski, H.: Cytokines and growth factors. Early gene expression during angiogenic stimuli. In Angiogenesis: Models, Modulators and clinical applications. Maragoudakis ME (Ed.). Plenum Press, New York, 1998, pp 349-353.
2. Ben-Yehudah, A. and Lorberboum-Galski, H.: GnRH-based chimeric proteins: future targeting therapy for adenocarcinomas? In “Current Topics in Biochemical Research” Research Trends, 4, 49-59, 2001.
3. Lorberboum-Galski. H.: Ligand-receptor interactions studied with chimeric proteins. In “Chimeric toxins: Mechanisms of action and therapeutic applications”. Lorberboum-Galski H and Luzarovici P (Eds) Taylor&Francis, New York, 2002, pp. 135-147.
4. Ben-Yehudah, A., Belostotsky, R., Aqeilan, R., Azar, Y., Steinberger, I., Fishman, A., Nechushtan, A., Yarkoni, S., and Lorberboum-Galski. H.: Chimeric proteins: a novel approach for eliminating specific cell populations for targeted human therapy.In “Chimeric toxins: Mechanisms of action and therapeutic applications”. Lorberboum-Galski H. and Luzarovici P. (Eds). Taylor&Francis, New York 2002, pp. 148-167.

Book

Chimeric toxins: Mechanisms of action and therapeutic applications. Lorberboum-Galski H. and Luzarovici P. (Eds). Taylor&Francis, New York, 2002.